DURECT (DRRX) Q3 2024 earnings summary

Executive summary

• Larsucosterol, the lead candidate, showed a 41–58% reduction in 90-day mortality in U.S. patients with alcohol-associated hepatitis in Phase 2b; a Phase 3 trial is planned pending $20–$25 million in funding, with topline results expected within two years of trial start.

• FDA granted Breakthrough Therapy and Fast Track Designations to larsucosterol; Phase 3 trial design incorporates FDA feedback, targets 200 patients, and may support NDA submission if successful.

• Innocoll Pharmaceuticals is terminating its POSIMIR license agreement effective May 2025; DURECT will regain U.S. rights and is evaluating next steps, with no material financial impact expected.

• Indivior discontinued PERSERIS sales and marketing in July 2024; future earn-out payments are expected to decline.

• No FDA-approved therapies currently exist for alcohol-associated hepatitis, representing a major unmet medical need.

Financial highlights

• Q3 2024 total revenues were $1.9 million, up from $1.7 million in Q3 2023, driven by higher product sales.

• Net loss for Q3 2024 was $4.3 million, compared to $3.0 million in Q3 2023.

• Cash, cash equivalents, and investments totaled $10.5 million at September 30, 2024, down from $29.8 million at December 31, 2023.

• Research and development expenses dropped to $2.2 million in Q3 2024 from $7.2 million in Q3 2023, mainly due to completion of the AHFIRM trial.

• Debt was $10.5 million at September 30, 2024, down from $16.7 million at December 31, 2023.

Outlook and guidance

• Sufficient cash is available to fund operations through Q1 2025, but substantial doubt exists about the ability to continue as a going concern for at least 12 months; additional capital is required to fund operations and the planned Phase 3 trial.

• Research and development and SG&A expenses are expected to remain comparable to Q3 2024 levels in the near term.

• Topline Phase 3 results anticipated within two years of trial initiation, contingent on securing funding.